Keith Choy - Haleon Plc President Pacific

HLN Stock  USD 9.65  0.10  1.05%   

President

Keith Choy is President Pacific of Haleon plc
Age 55
Address The Heights, Weybridge, United Kingdom, KT13 0NY
Phone44 1932 822000
Webhttps://www.haleon.com

Haleon Plc Management Efficiency

The company has Return on Asset of 0.0445 % which means that on every $100 spent on assets, it made $0.0445 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0682 %, implying that it generated $0.0682 on every 100 dollars invested. Haleon Plc's management efficiency ratios could be used to measure how well Haleon Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to 0.12. In addition to that, Return On Capital Employed is likely to drop to 0.04. At this time, Haleon Plc's Non Current Assets Total are very stable compared to the past year. As of the 25th of November 2024, Non Currrent Assets Other is likely to grow to about 435.8 M, while Total Assets are likely to drop about 27.7 B.
Haleon plc has 9.46 B in debt with debt to equity (D/E) ratio of 0.38, which is OK given its current industry classification. Haleon plc has a current ratio of 3.36, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Haleon to invest in growth at high rates of return.

Similar Executives

Showing other executives

PRESIDENT Age

Kathleen VeitTeva Pharma Industries
N/A
Sven DethlefsTeva Pharma Industries
55
Jeffrey MMSViatris
48
Andrew PlumpTakeda Pharmaceutical Co
59
Adam HaveyEmergent Biosolutions
53
MPharm MSDr Reddys Laboratories
61
David KinardElanco Animal Health
57
Ricardo PravdaCatalent
48
Aaron SchachtElanco Animal Health
52
Sherry PudloskiZoetis Inc
52
David StarkTeva Pharma Industries
55
Mark SabagTeva Pharma Industries
53
Tom PEngCatalent
56
Sarena LinElanco Animal Health
48
Etienne MontagutLantheus Holdings
49
James MeerElanco Animal Health
54
Roman TrawickiZoetis Inc
56
Hafrun FridriksdottirTeva Pharma Industries
58
Richard DaniellTeva Pharma Industries
57
Jonathan ArnoldCatalent
54
Sean KirkEmergent Biosolutions
45
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. Haleon Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 22000 people. Haleon plc (HLN) is traded on New York Stock Exchange in USA. It is located in The Heights, Weybridge, United Kingdom, KT13 0NY and employs 25,408 people. Haleon Plc is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Haleon plc Leadership Team

Elected by the shareholders, the Haleon Plc's board of directors comprises two types of representatives: Haleon Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haleon. The board's role is to monitor Haleon Plc's management team and ensure that shareholders' interests are well served. Haleon Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haleon Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Choy, President Pacific
Tamara Rogers, Chief Officer
Lisa Paley, President America
Adrian Morris, General Counsel
Brian McNamara, CEO Director
Bjarne Tellmann, General Counsel
Claire Dickson, Chief Officer
Bart Derde, Head Chain
Franck Riot, Chief Officer
Bjorn Timelin, Head Strategy
Tobias Hestler, Executive Officer
Amy Landucci, Head Technology
Namrata Patel, Chief Officer
Line Decker, Chief Officer
Jooyong Lee, Head CEO
Dawn Allen, CFO Director
Mairead Nayager, Chief Officer
Teri Lyng, Head Sustainability
Sonya Ghobrial, Head Relations
Ed Petter, Chief Officer
Filippo Lanzi, President LatAm

Haleon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haleon Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Haleon Plc

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Haleon Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Haleon Plc will appreciate offsetting losses from the drop in the long position's value.

Moving together with Haleon Stock

  0.64A Agilent Technologies Earnings Call TodayPairCorr
  0.84ME 23Andme HoldingPairCorr
  0.76JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Haleon Stock

  0.7MDGL Madrigal PharmaceuticalsPairCorr
  0.47KZR Kezar Life SciencesPairCorr
  0.4MLYS Mineralys Therapeutics,PairCorr
The ability to find closely correlated positions to Haleon Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Haleon Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Haleon Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Haleon plc to buy it.
The correlation of Haleon Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Haleon Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Haleon plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Haleon Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Haleon plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Haleon Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Haleon Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Haleon Plc Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haleon plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Haleon Stock, please use our How to Invest in Haleon Plc guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haleon Plc. If investors know Haleon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haleon Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.348
Dividend Share
0.062
Earnings Share
0.33
Revenue Per Share
2.446
Quarterly Revenue Growth
(0.01)
The market value of Haleon plc is measured differently than its book value, which is the value of Haleon that is recorded on the company's balance sheet. Investors also form their own opinion of Haleon Plc's value that differs from its market value or its book value, called intrinsic value, which is Haleon Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haleon Plc's market value can be influenced by many factors that don't directly affect Haleon Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haleon Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Haleon Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haleon Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.